Checks a blood test for colorectal cancer in adults with cancer or bowel disease
Tests a blood test for colorectal cancer in adults with other cancers or bowel disease.
Plain-language title generated from the registry record
Registry title: Observational Cross-reactivity Study for Colorectal Cancer Diagnosis
Key facts
- Where
- Madrid, Málaga, Ourense, and Oviedo, SpainSee the 5 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults diagnosed with one type of cancer other than colorectal cancer, or with a gastrointestinal disease. A blood sample is taken to check how often the colorectal cancer blood test gives a false positive result.
- Age
- Older than 18 years at the time of blood sample collection.
- Sex
- All sexes can join.
- Disease stage
- Diagnosed with only one type of cancer (not colorectal cancer) or a gastrointestinal disease. The cancer or disease must be properly staged or diagnosed.
- Earlier treatment
- Cannot have had chemotherapy or radiotherapy before. If there is a tumor, cannot have had total or partial surgical removal of it.
Main reasons for not taking part
- Previous chemotherapy or radiotherapy
- Total or partial surgical removal of the tumor
- Personal history of colorectal adenoma, serrated lesions, colorectal cancer, familial adenomatous polyposis or Lynch syndrome
- No appropriate staging or diagnosis
- Hemolyzed plasma
Read by machine on 12 November 2026.
Where in Spain
- Hospital Universitario HM SanchinarroMadrid, SpainContact: Marta JimenezTaking people
- MD Anderson Cancer CentreMadrid, SpainContact: Marta JimenezNo longer taking part
- Hospitales HM de MalagaMálaga, SpainContact: Marta JimenezTaking people
- Hospital Universitario de OurenseOurense, SpainContact: Marta JimenezTaking people
- Hospital Centro Médico AsturiasOviedo, SpainContact: Marta JimenezTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- ADVANCED MARKER DISCOVERY S.L.
- Trial code
- NCT06889844
- Record updated
- 1 October 2025
- Original description
The objective of this observational study is to evaluate the false positive rate of the blood test based on molecular biomarkers and risk factors. A total of 250 patients diagnosed with various cancers and gastrointestinal diseases will be enrolled. The main question to be answered isRead full original descriptionShow less
Observational Cross-reactivity Study to Evaluate the Specificity of a Blood Test for Colorectal Cancer Diagnosis Based on Molecular Markers and Risk Factors Identified With Artificial Intelligence Tools
The objective of this observational study is to evaluate the false positive rate of the blood test based on molecular biomarkers and risk factors. A total of 250 patients diagnosed with various cancers and gastrointestinal diseases will be enrolled. The main question to be answered is
Does the blood test have a low false positive rate in the main study population?
Participants will donate a blood sample as part of their regular medical care for cancer diagnosis and give the consent to know their clinical risk factors.
Inclusion: Patients older than 18 years of age at the time of blood sample collection; Subjects must be able to understand the information provided on the participant information sheet, must consent to participate in the study, and must sign the informed consent form; Patients diagnosed with only one type of cancer (no colorectal cacner) or gastrointestinal disease.
Exclusion: Patients who have received previous chemotherapy or radiotherapy; In case of diagnosis of a tumor: patients who have undergone total or partial surgical resection of the tumor; Patients with a personal history of advanced or non-advanced colorectal adenoma, serrated lesions, colorectal cancer, familial adenomatous polyposis or Lynch syndrome; Patients without appropriate staging or diagnosis; Patients with hemolyzed plasma.